Literature DB >> 23955872

Use of novel technology-based techniques to improve alcohol-related outcomes in clinical trials.

Eugenia M Gurvich1, George A Kenna, Lorenzo Leggio.   

Abstract

With a better understanding of the biologic basis of alcohol dependence and the considerable financial burden of alcohol abuse and dependence, the number of alcohol-related clinical pharmacotherapy trials has been on the rise. Subsequently, the potential to find efficacious treatments is more promising. Unfortunately, alcohol-related trials face a number of challenges, as a result of the difficulties that arise from traditional and outdated methods to collect data and ensure medication adherence. Novel technology-based assessments, such as ecological momentary assessment, interactive voice response, transdermal sensor and medication-event monitoring system provide a prospective solution-albeit not without possible concerns-to the difficulties faced in alcohol-related clinical trials. Clinical trials are meant to define the efficacy of the treatment and to determine an effective and safe dosage. However, due to lack of adherence a drug could inappropriately or mistakenly be judged as ineffective for treating a specific disorder. The described technologies may be important tools to prevent false negatives in validating drug efficacy, to provide consistency in clinical trials and to improve available data regarding the study of pharmacotherapies for alcohol dependence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23955872      PMCID: PMC3816323          DOI: 10.1093/alcalc/agt134

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN: 0735-0414            Impact factor:   2.826


  66 in total

Review 1.  Drug addiction, dysregulation of reward, and allostasis.

Authors:  G F Koob; M Le Moal
Journal:  Neuropsychopharmacology       Date:  2001-02       Impact factor: 7.853

Review 2.  Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research.

Authors:  H R Kranzler
Journal:  Alcohol Alcohol       Date:  2000 Nov-Dec       Impact factor: 2.826

3.  Studies on a wearable, electronic, transdermal alcohol sensor.

Authors:  R M Swift; C S Martin; L Swette; A LaConti; N Kackley
Journal:  Alcohol Clin Exp Res       Date:  1992-08       Impact factor: 3.455

4.  Validity of transdermal alcohol monitoring: fixed and self-regulated dosing.

Authors:  Joseph T Sakai; Susan K Mikulich-Gilbertson; Robert J Long; Thomas J Crowley
Journal:  Alcohol Clin Exp Res       Date:  2006-01       Impact factor: 3.455

Review 5.  Turning the clock ahead: potential preclinical and clinical neuropharmacological targets for alcohol dependence.

Authors:  Lorenzo Leggio; Silvia Cardone; Anna Ferrulli; George A Kenna; Marco Diana; Robert M Swift; Giovanni Addolorato
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

6.  Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence.

Authors:  Raymond F Anton; Darlene H Moak; Patricia Latham; L Randolph Waid; Hugh Myrick; Konstantin Voronin; Angelica Thevos; Wei Wang; Robert Woolson
Journal:  J Clin Psychopharmacol       Date:  2005-08       Impact factor: 3.153

7.  Field and laboratory alcohol detection with 2 types of transdermal devices.

Authors:  Paul R Marques; A Scott McKnight
Journal:  Alcohol Clin Exp Res       Date:  2009-01-21       Impact factor: 3.455

8.  Ecological momentary assessment in a behavioral drinking moderation training program.

Authors:  R L Collins; E T Morsheimer; S Shiffman; J A Paty; M Gnys; G D Papandonatos
Journal:  Exp Clin Psychopharmacol       Date:  1998-08       Impact factor: 3.157

9.  Ecological momentary assessment of adolescent smoking cessation: a feasibility study.

Authors:  Chad J Gwaltney; Rachel Bartolomei; Suzanne M Colby; Christopher W Kahler
Journal:  Nicotine Tob Res       Date:  2008-07       Impact factor: 4.244

10.  Compliance assessed by the Medication Event Monitoring System.

Authors:  N F Olivieri; D Matsui; C Hermann; G Koren
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

View more
  14 in total

Review 1.  Assessment of Alcohol Use in the Natural Environment.

Authors:  Thomas M Piasecki
Journal:  Alcohol Clin Exp Res       Date:  2019-03-01       Impact factor: 3.455

2.  Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial.

Authors:  George A Kenna; Carolina L Haass-Koffler; William H Zywiak; Steven M Edwards; Michael B Brickley; Robert M Swift; Lorenzo Leggio
Journal:  Addict Biol       Date:  2015-06-02       Impact factor: 4.280

3.  Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.

Authors:  Stephanie S O'Malley; William R Corbin; Robert F Leeman; Kelly S DeMartini; Lisa M Fucito; Jolomi Ikomi; Denise M Romano; Ran Wu; Benjamin A Toll; Kenneth J Sher; Ralitza Gueorguieva; Henry R Kranzler
Journal:  J Clin Psychiatry       Date:  2015-02       Impact factor: 4.384

Review 4.  Combining ecological momentary assessment with objective, ambulatory measures of behavior and physiology in substance-use research.

Authors:  Jeremiah W Bertz; David H Epstein; Kenzie L Preston
Journal:  Addict Behav       Date:  2017-11-16       Impact factor: 3.913

5.  GRIK1 genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate.

Authors:  Henry R Kranzler; Stephen Armeli; Howard Tennen; Joel Gelernter; Jonathan Covault
Journal:  Exp Clin Psychopharmacol       Date:  2014-12       Impact factor: 3.157

6.  Determining ethyl glucuronide cutoffs when detecting self-reported alcohol use in addiction treatment patients.

Authors:  Jessica M Lowe; Michael G McDonell; Emily Leickly; Frank A Angelo; Roger Vilardaga; Sterling McPherson; Debra Srebnik; John Roll; Richard K Ries
Journal:  Alcohol Clin Exp Res       Date:  2015-04-10       Impact factor: 3.455

Review 7.  Methods to reduce the incidence of false negative trial results in substance use treatment research.

Authors:  Rachel L Tomko; Erin A McClure; Lindsay M Squeglia; Hayley Treloar Padovano; Aimee L McRae-Clark; Nathaniel L Baker; Matthew J Carpenter; Kevin M Gray
Journal:  Curr Opin Psychol       Date:  2019-01-28

8.  High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-based mass spectrometry.

Authors:  Emily Leickly; Michael G McDonell; Roger Vilardaga; Frank A Angelo; Jessica M Lowe; Sterling McPherson; Debra Srebnik; John M Roll; Richard K Ries
Journal:  Am J Drug Alcohol Abuse       Date:  2015-02-19       Impact factor: 3.829

9.  What happens when people discontinue taking medications? Lessons from COMBINE.

Authors:  Robert L Stout; Jordan M Braciszewski; Meenakshi Sabina Subbaraman; Henry R Kranzler; Stephanie S O'Malley; Daniel Falk
Journal:  Addiction       Date:  2014-09-12       Impact factor: 6.526

Review 10.  Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-06       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.